Adaptive platform trials rather than randomised controlled trials for paediatric sepsis.

Area of Science:

• Pediatric critical care medicine
• Clinical trial methodology
• Infectious diseases

Background:

• Traditional randomized controlled trials (RCTs) for pediatric sepsis treatments often rely on inaccurate assumptions, leading to low-quality evidence.
• Existing evidence for pediatric sepsis interventions is frequently suboptimal due to the limitations of traditional trial designs.
• Adaptive platform trials (APTs) offer a more robust framework for evaluating multiple interventions concurrently.

Purpose of the Study:

• To introduce the Paediatric Adaptive Sepsis Platform Trial (PAPT) as an innovative approach for pediatric sepsis research.
• To leverage accrued data for adaptive trial modifications, enhancing efficiency and flexibility.
• To identify optimal treatments for pediatric sepsis through a more effective trial design.

Main Methods:

• Utilizing the infrastructure of the Paediatric Research in Emergency Departments International Collaborative (PEDRIC) network.
• Implementing an adaptive platform trial design to evaluate multiple interventions simultaneously.
• Assessing treatments including resuscitation fluids, vasoactive medications, corticosteroids, and antimicrobials.

Main Results:

• APTs utilize accrued data to dynamically adapt trial parameters, unlike traditional RCTs.
• Simultaneous evaluation of multiple treatments is possible within a shared research infrastructure.
• The proposed trial aims to generate high-quality evidence for pediatric sepsis interventions.

Conclusions:

• APTs represent a significant advancement over traditional RCTs for pediatric sepsis research.
• The Paediatric Adaptive Sepsis Platform Trial has the potential to substantially improve clinical practice.
• This innovative trial design could lead to a significant reduction in global pediatric sepsis mortality.